Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of the Purinostat Mesylate for Injection (PM) Compared to Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

NCT07011056 is registered in ClinicalTrials.gov with Chengdu Zenitar Biomedical Technology Co., Ltd as lead sponsor.

NCT NCT07011056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07011056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of the Purinostat Mesylate for Injection (PM) Compared to Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Lead sponsor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
July 18, 2025
Completion date
June 30, 2029
Enrollment
390 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent and refractory diffuse large b-cell lymphoma